Does an Intradermal Vaccination for Monkeypox Make Sense?

Area of Science:

• Vaccinology
• Immunology
• Public Health

Background:

• Recent pandemics underscore challenges in controlling highly transmissible viruses.
• Rapid vaccine development and deployment highlight strengths and weaknesses in global health responses.
• Compressed timelines for vaccine research, development, and clinical testing can create communication uncertainties.

Purpose of the Study:

• To provide background on intramuscular (IM), subcutaneous (SC), and intradermal (ID) vaccine administration routes.
• To discuss potential immunological outcomes associated with different injection sites.
• To address the FDA's decision regarding intradermal administration of a monkeypox vaccine as a dose-sparing strategy.

Main Methods:

• Review of existing literature on vaccine administration routes (IM, SC, ID).
• Analysis of immunological principles related to different injection sites.
• Examination of regulatory decisions and strategic considerations for vaccine deployment.

Main Results:

• Intramuscular (IM), subcutaneous (SC), and intradermal (ID) routes offer distinct immunological profiles.
• Intradermal (ID) administration of the monkeypox vaccine was approved by the FDA as a dose-sparing strategy.
• Subcutaneous (SC) injection was the initial approval route for the monkeypox vaccine.

Conclusions:

• Understanding vaccine administration routes is crucial for effective immunization strategies.
• Dose-sparing techniques, such as intradermal injection, can maximize vaccine availability during public health emergencies.
• Regulatory flexibility, informed by scientific understanding, is vital for responding to pandemics.